insights_auto
Why is ADAPY up 7.14%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.030
arrow_upward
+7.14%(+0.0020) 1D
Oct 9, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
$0.03
High
$0.03
Low
$0.03
Mkt. cap
7.42M
Avg. vol.
207.06K
Volume
77.40K
52-wk high
$0.24
52-wk low
$0.00
Beta
0.75
Shares outstanding
265.05M
No. of employees
272
Open
$0.03
High
$0.03
Low
$0.03
Mkt. cap
7.42M
Avg. vol.
207.06K
Volume
77.40K
52-wk high
$0.24
52-wk low
$0.00
Beta
0.75
Shares outstanding
265.05M
No. of employees
272
News stories
From web sources and news partners
MarketBeat
·
50 minutes ago
Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXIN) Stock Short Interest Drops 85.7%
MarketWatch
·
53 minutes ago
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
ChartMill
·
1 hour ago
XPEL (NASDAQ:XPEL): A GARP Stock with Profitable Growth and Reasonable Valuation
Yahoo Finance
·
20 hours ago
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR